Home | Contact Us 

Online Catalog

View our online catalog.
For further information or for a quotation, call 1-510-475-0650 or email us at

How Can We Help You?
Click here to contact us!


Sepragen Announces Letter of Intent to Acquire Assets of Process Equipment, Inc.

Union City, CA, November 16, 2000 -- Sepragen Corporation (OTC BB: SPGNA), a provider of patented technology and equipment for purification needs in the nutritional and biotech industries, today announced that it had signed a non-binding Letter of Intent to acquire certain assets of Process Equipment, Inc. The asset purchase would be subject to successful completion of a proposed financing, the execution of a definitive agreement, and appropriate approvals of the board and shareholders, as needed by each company. Said Vinit Saxena, Sepragen's CEO and Chairman, "This proposed transaction, when consummated, would provide Sepragen with not only additional revenues but also manufacturing and support infrastructure to leverage our technology base and build critical mass."

Sepragen Corporation is a leading supplier of separation process technology, equipment and consumables to the biotechnology and nutraceutical industries. In addition to its biotech drug separation business, the Company has developed patented applications that provide large market opportunities in the food and beverage industry, including debittering citrus juices, extracting isoflavone (plant estrogen) from soy, as well as extracting proteins from whey. The Company holds over 14 issued patents relating to its core technology.

Return to News Archives main page

The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Company | Products | News and Events | Contact Us | Terms and Conditions | Privacy Policy © 2020 Sepragen Corporation. All rights reserved. (510) 475-0650